Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Single-center phase 2 of daratumumab ± pomalidomide as maintenance post-ASCT finds ≥CR rate increased to 85%, MRD- (<10–5) in 75%; median PFS 45.1 months among pts w/ 2–4 prior treatments; 10 years RMST from dx of 9.8 years․”
Title: Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study
Authors: Oren Pasvolsky, Bruno Almeida Costa, Yosra M. Aljawai, Krina K. Patel, Qaiser Bashir, Dawen Sui, Samer A. Srour, Mark R. Tanner, Uday R. Popat, Neeraj Y. Saini, Chitra Hosing, Jeremy L. Ramdial, Hans C. Lee, Gregory P. Kaufman, Sheeba K. Thomas, Donna M. Weber, Melody Becnel, Guilin Tang, Robert Z. Orlowski, Richard E. Champlin, Yago Nieto, Elizabeth J. Shpall, Muzaffar H. Qazilbash.
You can read the full article on Blood Cancer Journal.
You can find other articles featuring Robert Orlowski on OncoDaily.
